ASCO
0
ASCO 2025 Recap: Rise of the Bispecifics, Dueling Degraders, ADCs of Interest & More
0

Bispecific antibodies are one of the most active areas of cancer research, and pharmaceutical companies are busy striking deals to add them to ...

0
Kura Oncology Drug’s Data at ASCO Support FDA Filing Now Under Priority Review for Leukemia
0

A Kura Oncology and Kyowa Kirin-partnered drug vying to become the first FDA-approved treatment for cases of acute myeloid leukemia (AML) carrying ...

0
Transformation in telecommunication infrastructure | ASCO Power Technologies
0

This audio was created using Microsoft Azure Speech ServicesOn February 21 2021, Bablu Kazi held his phone to my face and shared how it had more powerful ...

Som2ny Network
Logo
Compare items
  • Total (0)
Compare
0